VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Company Registration Number:
15278963 (England and Wales)

Unaudited statutory accounts for the year ended 30 November 2025

Period of accounts

Start date: 1 December 2024

End date: 30 November 2025

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Contents of the Financial Statements

for the Period Ended 30 November 2025

Balance sheet
Additional notes
Balance sheet notes

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Balance sheet

As at 30 November 2025

Notes 2025 13 months to 30 November 2024


£

£
Fixed assets
Investments: 3 1,839,110 1,839,110
Total fixed assets: 1,839,110 1,839,110
Current assets
Debtors: 4 759,803 360,398
Total current assets: 759,803 360,398
Creditors: amounts falling due within one year: 5 ( 759,803 ) ( 360,398 )
Net current assets (liabilities): 0 0
Total assets less current liabilities: 1,839,110 1,839,110
Total net assets (liabilities): 1,839,110 1,839,110
Capital and reserves
Called up share capital: 1,390 1,390
Share premium account: 1,837,720 1,837,720
Total Shareholders' funds: 1,839,110 1,839,110

The notes form part of these financial statements

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Balance sheet statements

For the year ending 30 November 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 15 October 2026
and signed on behalf of the board by:

Name: Louise Josefina Nilsson
Status: Director

The notes form part of these financial statements

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Notes to the Financial Statements

for the Period Ended 30 November 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

    Other accounting policies

    Investments Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account. Debtors Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts. Creditors Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. Taxation A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted. Foreign currency translation Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Notes to the Financial Statements

for the Period Ended 30 November 2025

  • 2. Employees

    2025 13 months to 30 November 2024
    Average number of employees during the period 0 0

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Notes to the Financial Statements

for the Period Ended 30 November 2025

3. Fixed assets investments note

Other investments – cost At 1 December 2024: £1,839,110 Additions: £nil At 30 November 2025: £1,839,110 The investment comprises shares in the subsidiary undertaking, measured at cost less any accumulated impairment losses. No impairment has been recognised.

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Notes to the Financial Statements

for the Period Ended 30 November 2025

4. Debtors

2025 13 months to 30 November 2024
£ £
Other debtors 759,803 360,398
Total 759,803 360,398

Other debtors comprise amounts owed by group undertakings and undertakings in which the company has a participating interest. At 30 November 2025 this represents loans to a subsidiary totalling SEK 9,500,040, translated at the closing rate of SEK 12.5033 = £1.

VIRONOVA BIOANALYTICS HOLDINGS LIMITED

Notes to the Financial Statements

for the Period Ended 30 November 2025

5. Creditors: amounts falling due within one year note

2025 13 months to 30 November 2024
£ £
Other creditors 759,803 360,398
Total 759,803 360,398